Hepatitis B
Conditions
Brief summary
Hepatitis B virus (HBV) infection is a challenging health problem. According to the World Health Organization, an estimated 240 million individuals (3.7%) suffered from chronic HBV infection worldwide. After acute hepatitis B virus (HBV) infection, the disappearance of hepatitis B surface antigen (HBsAg) had generally been believed to signify viral elimination. However, it now becomes clear that those subjects may have occult HBV infection which is defined as the presence of HBV DNA in the liver in the absence of HBsAg in the serum. Occult HBV infection usually accompanies antibody against hepatitis B core antigen (anti-HBc) and/or antibody against HBsAg (anti-HBs), but some cases might not have these serological markers (seronegative occult HBV infection) .
Detailed description
In a recent systematic review, nearly 40% of HBsAg carriers and 5% of antiHBc-positive but HBsAg-negative patients developed HBVr during TNF inhibitor therapy. Considering the lifelong use of multiple antirheumatic drugs, we need more specific guidelines for the management of rheumatic disease patients who are scheduled to receive biological and/or non-biological DMARDs.
Interventions
OTHERHBV core antibodies testing. • Real time PCR testing.
* HBV core antibodies testing in HBV surface antigen negative patients. * Real time PCR testing for those having positive HBc antibodies.
Sponsors
Sherief Abd-Elsalam
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE
Eligibility
Sex/Gender
ALL
Healthy volunteers
No
Inclusion criteria
* • Any patients with rheumatic disease with hepatitis B surface antigen negative.
Exclusion criteria
* • Overt co-morbid condition. * Any malignancy e.g. HCC
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of patients with occult HBV. | 1 year | Number of patients having occult HBV. |
Countries
Egypt
Contacts
Primary ContactSherief Abd-Elsalam, Consultant
Outcome results
None listed